Phase I Study of Oral Beta-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma.
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2013
At a glance
- Drugs Beta glucan (Primary) ; Monoclonal antibody 3F8 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jun 2007 Interim results have been reported.
- 25 Sep 2005 New trial record.